Aktuellt
SENASTE
Redeye provides an update following SenzaGen’s Q2 2024 report. Sales continue to grow steadily; however, a bit under our estimate. We make some minor sales estimate changes, resulting in an updated fair value range. Concludingly, we argue that the investment case is intact and that the share is currently traded at attractive levels.
LÄS MER
